2013;61:1799 808. 73. Mangner N, Stachel G, Woitek F, et al. Predictors of mortality and symp- tomatic outcome of patients with low-flow severe aortic stenosis under- going transcatheter aortic valve replacement. J Am Heart Assoc. 2018;7: e010287. 74. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38: 2739 91. 75. Ozkan A, Hachamovitch R, Kapadia SR, et al. Impact of aortic valve re- placement on outcome of symptomatic patients with severe aortic ste- nosis with low gradient and preserved left ventricular ejection fraction. Circulation. 2013;128:622 31. 76. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvas- tatin on progression of aortic stenosis: results of the Aortic Stenosis Pro- gression Observation: Measuring Effects Of Rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306 14. 77. Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of quantita- tive exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation. 2005;112:I377 82. 78. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J. 2005;26:1309 13. 79. Alborino D, Hoffmann JL, Fournet PC, et al. Value of exercise testing to evaluate the indication for surgery in asymptomatic patients with valvular aortic stenosis. J Heart Valve Dis. 2002;11:204 9. 80. Takeda S, Rimington H, Chambers J. Prediction of symptom-onset in aortic stenosis: a comparison of pressure drop/flow slope and haemodynamic measures at rest. Int J Cardiol. 2001;81:131 7. 81. Skalski J, Allison TG, Miller TD. The safety of cardiopulmonary exercise testing in a population with high-risk cardiovascular diseases. Circulation. 2012;126:2465 72. 82. Dayan V, Vignolo G, Magne J, et al. Outcome and impact of aortic valve replacement in patients with preserved LVEF and low-gradient aortic ste- nosis. J Am Coll Cardiol. 2015;66:2594 603. 3.2.4. 